Oncology at Huashan Hospital Shanghai | CMCS

Expert Cancer Care at One of China's Premier Academic Medical Centers

The Department of Oncology at Huashan Hospital — affiliated with Fudan University — is one of China's most distinguished oncology centers, with particular strengths in neuro-oncology, precision oncology, immunotherapy, and the multidisciplinary management of complex cancers. The department's unique integration with Huashan's world-renowned neurology and neurosurgery departments creates an unparalleled neuro-oncology program — one of the finest in China — for patients with brain tumors, spinal cord tumors, leptomeningeal metastases, and neurological complications of cancer and cancer treatment.

For international patients seeking expert oncology care in Shanghai — whether for a brain tumor, a solid tumor requiring precision molecular-guided therapy, immunotherapy, or a second opinion on a complex cancer diagnosis — Huashan Hospital's oncology department offers a level of expertise and multidisciplinary integration that is among the finest in China. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their cancer care journey.

About the Department

Huashan Hospital's oncology department is a national key clinical specialty operating dedicated oncology wards, a comprehensive outpatient oncology clinic, a chemotherapy and immunotherapy infusion center, a precision oncology and molecular tumor board, a neuro-oncology program, a palliative care service, and subspecialty clinics for brain tumors, lung cancer, gastrointestinal cancers, and other major tumor types. The department works in close collaboration with neurosurgery, neurology, radiation oncology, pathology, and molecular diagnostics through a dedicated multidisciplinary tumor board (MDT).

The department's molecular diagnostics program is a particular strength, providing comprehensive next-generation sequencing (NGS) tumor profiling, liquid biopsy, and biomarker testing to guide precision oncology treatment decisions. Faculty members publish regularly in leading oncology journals including Journal of Clinical Oncology, Cancer Cell, Nature Cancer, Neuro-Oncology, and Annals of Oncology.

Conditions Treated

Neuro-Oncology (A Center of Excellence)

• Glioblastoma (GBM) — Stupp protocol (temozolomide + radiation); tumor treating fields (TTFields/Optune); bevacizumab for recurrent GBM; MGMT methylation-guided therapy; clinical trial access for novel agents (IDH inhibitors, EGFR inhibitors, immunotherapy combinations)
• IDH-Mutant Glioma (Grade 2-3) — IDH inhibitors (vorasidenib for grade 2-3 IDH-mutant glioma); temozolomide and PCV chemotherapy; radiation therapy
• Brain Metastases — Stereotactic radiosurgery (SRS); whole brain radiation therapy; systemic therapy optimization for CNS penetration; leptomeningeal metastasis management
• Leptomeningeal Metastases — Intrathecal chemotherapy; systemic therapy with CNS penetration; palliative management
• Primary CNS Lymphoma — High-dose methotrexate-based induction; rituximab combinations; autologous stem cell transplantation consolidation; ibrutinib for relapsed disease
• Spinal Cord Tumors — Systemic therapy coordination after surgical resection; radiation therapy
• Neurological Complications of Cancer — Paraneoplastic syndromes; immune-related adverse events (irAEs) from checkpoint inhibitors; chemotherapy-induced peripheral neuropathy; radiation necrosis

Lung Cancer

• Non-Small Cell Lung Cancer (NSCLC) — Comprehensive molecular profiling (EGFR, ALK, ROS1, KRAS G12C, MET, RET, NTRK, BRAF); targeted therapy (osimertinib, alectinib, lorlatinib, sotorasib, adagrasib, tepotinib, selpercatinib, larotrectinib, dabrafenib/trametinib); PD-1/PD-L1 immunotherapy (pembrolizumab, nivolumab, atezolizumab, durvalumab); antibody-drug conjugates (trastuzumab deruxtecan for HER2-mutated NSCLC)
• Small Cell Lung Cancer (SCLC) — Platinum-etoposide with atezolizumab or durvalumab; prophylactic cranial irradiation; lurbinectedin for relapsed disease
• Mesothelioma — Nivolumab + ipilimumab; platinum-pemetrexed chemotherapy

Gastrointestinal Cancers

• Colorectal Cancer — FOLFOX, FOLFIRI, FOLFOXIRI; bevacizumab and cetuximab/panitumumab for RAS wild-type; pembrolizumab for MSI-H/dMMR; BRAF V600E-targeted therapy (encorafenib + cetuximab); fruquintinib and trifluridine/tipiracil for refractory disease
• Gastric & GEJ Cancer — FLOT perioperative chemotherapy; trastuzumab for HER2-positive; nivolumab + chemotherapy; trastuzumab deruxtecan for HER2-low; ramucirumab; zolbetuximab for CLDN18.2-positive
• Hepatocellular Carcinoma (HCC) — Atezolizumab + bevacizumab; sintilimab + bevacizumab; sorafenib, lenvatinib; TACE and HAIC coordination; regorafenib and cabozantinib for second-line
• Cholangiocarcinoma — Gemcitabine + cisplatin + durvalumab; IDH1 inhibitors (ivosidenib); FGFR2 inhibitors (pemigatinib, infigratinib, futibatinib); KRAS G12C inhibitors
• Pancreatic Cancer — FOLFIRINOX and gemcitabine + nab-paclitaxel; PARP inhibitors for BRCA-mutated; KRAS G12D inhibitors in clinical trials
• Esophageal Cancer — Nivolumab + chemotherapy; pembrolizumab for PD-L1-positive; chemoradiation coordination

Genitourinary Cancers

• Prostate Cancer — Novel hormonal agents; PARP inhibitors; lutetium-177 PSMA therapy coordination
• Bladder & Urothelial Cancer — Pembrolizumab, atezolizumab; enfortumab vedotin; sacituzumab govitecan; erdafitinib for FGFR-altered disease
• Renal Cell Carcinoma — Nivolumab + ipilimumab; pembrolizumab + axitinib; cabozantinib + nivolumab; belzutifan for VHL-associated RCC

Breast Cancer

• HER2-Positive Breast Cancer — Trastuzumab + pertuzumab; T-DM1; trastuzumab deruxtecan (T-DXd); tucatinib + capecitabine + trastuzumab for brain metastases
• Triple-Negative Breast Cancer — Pembrolizumab + chemotherapy; sacituzumab govitecan; olaparib for BRCA-mutated
• HR-Positive Breast Cancer — CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib); PI3K inhibitors (alpelisib for PIK3CA-mutated); elacestrant for ESR1-mutated; AKT inhibitors (capivasertib)

Hematological Malignancies

• Lymphoma — R-CHOP and novel regimens; CAR-T cell therapy coordination with hematology; bispecific antibodies (mosunetuzumab, glofitamab, epcoritamab)
• Leukemia & Myeloma — Coordination with hematology for complex cases requiring oncological input

Other Solid Tumors

• Head & Neck Cancer — Pembrolizumab for PD-L1-positive HNSCC; cetuximab; chemoradiation coordination
• Thyroid Cancer — Targeted therapy for RAI-refractory differentiated thyroid cancer; selpercatinib for RET-mutated MTC
• Sarcoma — Doxorubicin-based chemotherapy; imatinib for GIST; trabectedin; pazopanib
• Melanoma — BRAF/MEK inhibitors; PD-1 immunotherapy; ipilimumab + nivolumab
• Neuroendocrine Tumors — Somatostatin analogues; PRRT; everolimus; sunitinib
• Cancer of Unknown Primary (CUP) — Comprehensive molecular profiling for tissue-of-origin determination; site-specific therapy

Precision Oncology & Molecular Tumor Board

Huashan's precision oncology program is one of the most advanced in Shanghai, providing comprehensive molecular profiling to guide individualized cancer treatment:

• Comprehensive Genomic Profiling (CGP) — Next-generation sequencing of 300-500+ cancer genes to identify actionable mutations, fusions, and copy number alterations
• Liquid Biopsy (ctDNA) — Cell-free DNA analysis for treatment monitoring, resistance mechanism identification, and minimal residual disease detection
• Tumor Mutational Burden (TMB) & MSI Testing — Biomarker-guided immunotherapy selection
• HER2, PD-L1, NTRK, RET, ALK, ROS1 Testing — Companion diagnostic testing for targeted therapy eligibility
• Molecular Tumor Board — Weekly multidisciplinary review of complex molecular profiling results to identify optimal targeted therapy strategies, including off-label and clinical trial options

Immunotherapy Program

Huashan's oncology department has extensive experience with the full range of approved cancer immunotherapies:

• PD-1/PD-L1 Checkpoint Inhibitors — Pembrolizumab, nivolumab, atezolizumab, durvalumab, and sintilimab across multiple tumor types
• CTLA-4 Inhibitors — Ipilimumab in combination with nivolumab for melanoma, RCC, NSCLC, and other tumors
• Bispecific Antibodies — Mosunetuzumab, glofitamab, and epcoritamab for B-cell lymphoma
• Antibody-Drug Conjugates (ADCs) — Trastuzumab deruxtecan, sacituzumab govitecan, enfortumab vedotin, and other ADCs
• Immune-Related Adverse Event (irAE) Management — Expert management of immunotherapy toxicities in collaboration with relevant subspecialties

Palliative Care & Supportive Oncology

Huashan's palliative care service provides expert symptom management and supportive care for patients with advanced cancer:

• Pain management including opioid optimization and interventional pain procedures
• Nausea, fatigue, and other symptom management
• Nutritional support and cachexia management
• Psychological support and advance care planning
• Coordination of home-based and hospice care

Why International Patients Choose Huashan Oncology

• Neuro-Oncology Excellence — China's premier neuro-oncology program, uniquely integrated with the country's top neurology and neurosurgery departments
• Precision Oncology Leadership — Comprehensive genomic profiling and molecular tumor board for personalized treatment planning
• Immunotherapy Expertise — Extensive experience with checkpoint inhibitors, bispecific antibodies, and ADCs across all major tumor types
• irAE Management — Specialist expertise in immune-related adverse events leveraging Huashan's multidisciplinary subspecialty network
• Clinical Trial Access — Active participation in national and international trials for novel targeted and immunotherapy agents
• Cost-Effectiveness — World-class cancer care at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your cancer diagnosis, pathology reports, molecular profiling results, imaging, prior treatment history, and current medications with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate oncologist based on your tumor type — neuro-oncology, lung, GI, GU, breast, or precision oncology.
4. MDT Submission — Where appropriate, we facilitate pre-arrival case review by Huashan's multidisciplinary tumor board.
5. Priority Scheduling — We secure a consultation with minimal waiting time.
6. Travel & Logistics — Assistance with visa invitation letters, accommodation near Huashan Hospital, and Shanghai airport transfers.
7. Treatment Coordination — Full coordination of molecular profiling, imaging, chemotherapy/immunotherapy scheduling, and clinical trial enrollment.
8. Post-Treatment Follow-Up — Pathology and molecular profiling report translation, treatment response assessment, and remote follow-up after you return home.

Book a Consultation

If you are seeking expert oncology care in Shanghai — whether for a brain tumor, lung cancer, GI cancer, breast cancer, a rare tumor, or a second opinion on a complex cancer diagnosis — CMCS can arrange a specialist consultation with Huashan Hospital's oncology team.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com